Dinabolyn (Methandienone)

About the Product

Dinabolyn is a research compound from Driada Medical, containing Methandienone (also known as Methandrostenolone) . This is a synthetic anabolic-androgenic steroid (AAS) derived from testosterone. Its molecular formula is C₂₀H₂₈O₂ with a molecular weight of 300.4 g/mol and a CAS number of 72-63-9 .

The compound features a 17α-alkylated structure with a double bond between carbons 1 and 2 (Δ¹ modification) . These structural modifications serve specific research purposes:

• The 17α-methyl group provides steric hindrance against hepatic oxidation, enabling oral bioavailability in research models .

• The Δ¹ double bond impedes 5α-reductase conversion, differentiating its receptor binding kinetics from non-Δ¹ androgens .

The product is intended for laboratory research use only and features an integrated QR code on the packaging for detailed product verification.

• Product Name: Dinabolyn (Methandienone)

• Brand: Driada Medical

• Form: Solution for research applications

• CAS: 72-63-9

• For Research Use Only.

Research Applications & Mechanism of Action

• Androgen Receptor Agonist: Methandienone functions as an agonist at the androgen receptor (AR), the biological target of androgens like testosterone. Upon AR binding, the activated receptor-hormone complex translocates to the nucleus, binds to androgen response elements (AREs), and modulates transcription of genes involved in protein synthesis and cellular growth .

• Quantified Anabolic:Androgenic Ratio: Relative to the testosterone baseline (100:100), Methandienone is characterized by an anabolic:androgenic ratio of 200:50 . Its dissociation index is in the range of 2–3, compared to a range of 3–10 for several other anabolic agents . This indicates a less selective anabolic profile relative to certain in-class alternatives .

• Protein Anabolism Research: The primary mechanism behind Methandienone's muscle-building capacity is its ability to increase protein synthesis and enhance nitrogen retention within muscle cells . A positive nitrogen balance (where nitrogen intake exceeds excretion) is a key indicator of an anabolic state . This property can be studied in models of muscle physiology and metabolic research.

• SHBG Affinity Studies: Methandienone displays a very low affinity for human serum sex hormone-binding globulin (SHBG), quantified as approximately 10% of testosterone's affinity and 2% of DHT's affinity . This results in a significantly larger fraction of the compound circulating in the free, unbound state (the pharmacologically active form), influencing its bioavailability .

• Metabolic Research: Methandienone's moderate androgenic and estrogenic effects provide avenues for research into lipid metabolism, glucose homeostasis, and endocrine regulation.

Research & Scientific Background

• Historical & Chemical Background: Methandienone was first synthesized in 1955 by researchers at CIBA and introduced to the U.S. market in 1958. It is a 17α-alkylated derivative of testosterone . The C1-C2 double bond reduces its androgenic activity relative to its anabolic effects .

• Androgen Receptor Binding Research: Computational docking studies of several oral anabolic steroids with the human androgen receptor ligand-binding domain (hARLBD) show that Methandienone registers a distinct binding energy profile, differentiating it from methyltestosterone, oxandrolone, and stanozolol in receptor interaction kinetics . Its rank order in AR binding affinity is situated differently from nandrolone and testosterone .

• Hepatotoxicity Research: The 17α-alkylated structure that confers oral bioavailability is also associated with potential hepatotoxic effects. Recent research (2026) demonstrates that metandienone exposure in HepG2 cells reduced cell viability to 88.01% and increased the apoptosis rate to 25.08%. RNA transcriptome data showed significant alteration of 221 genes closely related to liver metabolism, oxidative stress, and inflammatory response . This makes Methandienone a key compound for studies on AAS-induced liver injury mechanisms.

• Metabolism & Detection Research: Human excretion studies show that 6β-hydroxylation is a major metabolic pathway for Methandienone . Recent research (2025) has identified novel metabolites, including E3 (17α-hydroxymethyl-17β-methyl-18-nor-5β-androsta-1,13-dien-3α-ol), which is being investigated as a potential long-term marker in anti-doping research .

• Genetic Variability Research: Research into genetic polymorphisms affecting metabolism is an emerging area. While direct studies on Methandienone are limited, the field of pharmacogenomics indicates that genetic variations in drug-metabolizing enzymes can influence compound response. Studies on compounds like methadone have shown that polymorphisms in genes such as CYP2B6, CYP2C19, and ABCB1 can affect clearance and concentrations . This suggests potential avenues for investigating how genetic factors may influence individual responses to Methandienone in research models.